Primary Outcome Measures
Number of Participants With Adverse Events [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RPTD) of ABBV-011 [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RPTD) of ABBV-011 in Combination with Budigalimab [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Number of Participants With Dose Limiting Toxicities (DLTs) [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Mean Change from Baseline in Vital Signs [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Incidence of Laboratory Abnormaities [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Mean Change from Baseline in Electrocardiogram (ECG) Parameters [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Secondary Outcome Measures
Maximum Serum Concentration (Cmax) of ABBV-011 [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Area Under the Serum Concentration-Time Curve (AUCinf) of ABBV-011 [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Area Under the Serum Concentration-Time Curve from 0 to Last Measurable Concentration (AUC0-t) of ABBV-011 [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Time to Maximum Serum Concentration (Tmax) of ABBV-011 [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Observed Serum Concentration at Trough (Ctrough) of ABBV-011 [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Apparent Terminal Half-Life (T1/2) of ABBV-011 [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Accumulation Ratio of ABBV-011 [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Serum Clearance (CL) of ABBV-011 [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Steady State Volume of Distribution (Vss) of ABBV-011 [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Incidence of Antidrug Antibodies (ADA) Against ABBV-011 or Budigalimab (ABBV-181) [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Clinical Benefit Rate (CBR) [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Duration of Response (DOR) [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Duration of Clinical Benefit (DOCB) [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Progression-Free Survival (PFS) [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]
Overall Survival (OS) [Time Frame: Up to approximately 5 years after the first participant receives first dose of study drug] [Designated as safety issue: ]